Brokerages Expect Aptinyx Inc (NASDAQ:APTX) Will Announce Earnings of -$0.47 Per Share

Share on StockTwits

Wall Street analysts predict that Aptinyx Inc (NASDAQ:APTX) will report ($0.47) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Aptinyx’s earnings. The lowest EPS estimate is ($0.51) and the highest is ($0.45). Aptinyx posted earnings of ($0.43) per share in the same quarter last year, which would suggest a negative year over year growth rate of 9.3%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Aptinyx will report full year earnings of ($1.95) per share for the current fiscal year, with EPS estimates ranging from ($2.16) to ($1.65). For the next financial year, analysts forecast that the company will report earnings of ($1.79) per share, with EPS estimates ranging from ($2.00) to ($1.62). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Aptinyx.

Aptinyx (NASDAQ:APTX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.16. Aptinyx had a negative return on equity of 40.01% and a negative net margin of 1,504.24%. The firm had revenue of $0.93 million for the quarter, compared to analyst estimates of $0.95 million.

APTX has been the topic of several research reports. Cowen restated a “buy” rating on shares of Aptinyx in a research note on Monday, June 10th. Cantor Fitzgerald restated a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. ValuEngine upgraded Aptinyx from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. lowered Aptinyx from a “neutral” rating to an “underweight” rating in a research note on Tuesday, August 13th. Finally, Svb Leerink began coverage on Aptinyx in a research note on Thursday, June 20th. They issued an “outperform” rating and a $12.00 price objective on the stock. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $12.63.

APTX traded down $0.19 on Tuesday, hitting $3.06. 96,931 shares of the stock traded hands, compared to its average volume of 331,368. Aptinyx has a 52 week low of $2.88 and a 52 week high of $32.25. The firm has a market capitalization of $103.70 million, a PE ratio of -1.16 and a beta of -0.03. The business has a fifty day moving average price of $3.52 and a two-hundred day moving average price of $3.92.

Hedge funds have recently added to or reduced their stakes in the company. A.R.T. Advisors LLC grew its position in Aptinyx by 15.9% during the 2nd quarter. A.R.T. Advisors LLC now owns 27,000 shares of the company’s stock worth $90,000 after acquiring an additional 3,695 shares during the last quarter. Gabelli Funds LLC grew its position in Aptinyx by 45.9% during the 2nd quarter. Gabelli Funds LLC now owns 15,901 shares of the company’s stock worth $53,000 after acquiring an additional 5,000 shares during the last quarter. Bank of New York Mellon Corp grew its position in Aptinyx by 30.6% during the 4th quarter. Bank of New York Mellon Corp now owns 43,887 shares of the company’s stock worth $726,000 after acquiring an additional 10,284 shares during the last quarter. Bank of America Corp DE grew its position in Aptinyx by 430.0% during the 4th quarter. Bank of America Corp DE now owns 13,213 shares of the company’s stock worth $218,000 after acquiring an additional 10,720 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Aptinyx during the 2nd quarter worth approximately $49,000. Institutional investors own 57.49% of the company’s stock.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

See Also: Quiet Period

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.